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ABSTRACT
Introduction Delirium in critically ill adults is associated 
with prolonged hospital stay, increased mortality and 
greater cognitive and functional decline. Current practice 
guideline recommendations advocate the use of non- 
pharmacological strategies to reduce delirium. The 
routine use of scheduled haloperidol to treat delirium is 
not recommended given a lack of evidence regarding its 
ability to resolve delirium nor improve relevant short- term 
and longer- term outcomes. This study aims to evaluate 
the efficacy and safety of haloperidol for the treatment of 
delirium in adult critically ill patients to reduce days spent 
with coma or delirium.
Methods and analysis EuRIDICE is a prospective, multi- 
centre, randomised, double- blind, placebo- controlled 
trial. Study population consists of adult intensive care 
unit (ICU) patients without acute neurological injury who 
have delirium based on a positive Intensive Care Delirium 
Screening Checklist (ICDSC) or Confusion Assessment 
Method for the ICU (CAM- ICU) assessment. Intervention 
is intravenous haloperidol 2.5 mg (or matching placebo) 
every 8 hours, titrated daily based on ICDSC or CAM- 
ICU positivity to a maximum of 5 mg every 8 hours, 
until delirium resolution or ICU discharge. Main study 
endpoint is delirium and coma- free days (DCFD) up 
to 14 days after randomisation. Secondary endpoints 
include (1) 28- day and 1- year mortality, (2) cognitive and 
functional performance at 3 and 12 months, (3) patient 
and family delirium and ICU experience, (4) psychological 
sequelae during and after ICU stay, (4) safety concerns 
associated with haloperidol use and (5) cost- effectiveness. 
Differences in DCFDs between haloperidol and placebo 
group will be analysed using Poisson regression analysis. 
Study recruitment started in February 2018 and continues.
Ethics and dissemination The study has been approved 
by the Medical Ethics Committee of the Erasmus University 
Medical Centre Rotterdam (MEC2017-511) and by the 
Institutional Review Boards of the participating sites. Its 
results will be disseminated via peer- reviewed publication 
and conference presentations.
Trial registration NCT03628391
INTRODUCTION
Delirium occurs in up to 80% of patients 
admitted to the intensive care unit (ICU)1 2 and 
is associated with greater ICU and post- ICU 
mortality.2 Cognitive dysfunction and func-
tional decline after critical illness is common, 
frequently persists for months after ICU 
discharge and is worse among patients who 
experience delirium.2 3 The symptoms and 
sequelae of delirium, including fear, anxiety, 
disrupted sleep and post- traumatic stress 
disorder, may persist for months after ICU 
discharge. The health and societal costs of 
delirium are estimated to exceed $10 billion 
per year in the USA alone.4
Strengths and limitations of this study
 ► This study is the first sufficiently powered ran-
domised, multi- centre, double- blind, placebo- 
controlled clinical trial in Europe.
 ► Extensive neurocognitive testing will be conducted 
with a valid test battery in order to assess cognitive 
impairment at 3 and 12 months after intensive care 
unit (ICU) admission.
 ► We will assess patient and family experiences asso-
ciated with delirium as a novel outcome.
 ► There are little data on the optimal haloperidol 
regimen in ICU patients; the maximum haloper-
idol dose of 15 mg/day in our study may still be 
subtherapeutic.
 ► Lack of true clinical equipoise among nurses and 
physicians regarding the use of haloperidol may 
hamper motivation for the study.
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Given the burden and costs of delirium in critically ill 
adults, substantial research efforts have been devoted to 
identify safe and effective strategies to treat it. Current 
evidence and practice guideline recommendations advo-
cate the use of non- pharmacological strategies to reduce 
delirium, including avoidance of benzodiazepine seda-
tion, early mobilisation and the use of sleep improve-
ment protocols. The routine use of medication- based 
interventions to treat delirium, other than treatments to 
reduce the agitation that sometimes accompanies it, are 
not recommended.5 6 The routine use of scheduled halo-
peridol to treat delirium is not currently recommended 
given a lack of current evidence regarding its ability to 
resolve delirium and its symptoms, nor improve relevant 
short and longer- term outcomes.
At the time this protocol was finalised, two randomised, 
placebo- controlled trials had evaluated haloperidol for 
ICU delirium prophylaxis or treatment and found halo-
peridol use did not affect days spent with delirium, days 
of mechanical ventilation, nor time spent in the ICU or 
hospital.7 8 In one of these randomised controlled trials, 
haloperidol use was associated with less agitation.7 Impor-
tantly, both studies were small (a combined total of 212 
patients were enrolled), the ABCDEF bundle (a multi-
modal ICU bundle shown to reduce delirium by 50%)9 was 
not routinely used, the effect of haloperidol on delirium- 
related symptoms was not evaluated and the post- ICU, 
longer- term outcomes were not considered. Whether the 
response to haloperidol was different between patients 
with hyperactive versus hypoactive delirium was also not 
evaluated. The impact of haloperidol on patients’ and 
families’ experiences with delirium after ICU discharge 
remains unknown. Whether long- term mortality is caus-
ally related to delirium or simply the persistent cognitive 
and functional decline associated with critical illness can 
only be established through a randomised trial.10 More-
over, the use of haloperidol in critically ill adults is not 
without potential safety concerns given it may prolong 
the QTc interval, induce extrapyramidal effects and cause 
oversedation. Despite haloperidol’s lack of proven effi-
cacy and the safety concerns associated with its use, halo-
peridol continues to be widely used in ICUs to treat of 
delirium.11
In light of the aforementioned evidence gaps that 
were identified at the time this trial was conceptualised, 
there is a clear need for a large, multi- centre, randomised 
controlled trial to better define the efficacy and safety of 
haloperidol to treat delirium in critically ill adults. This 
report describes the protocol for a large, multi- centre, 
randomised, placebo- controlled, haloperidol delirium 
trial that recently started enrolling patients across 
multiple ICUs in the Netherlands.
METHODS AND ANALYSIS
Study design
Randomised, double- blind, placebo- controlled trial of 
haloperidol for the treatment of delirium in patients 
admitted to one of six participating ICUs in the 
Rotterdam area in the Netherlands. See online supple-
mental appendix 1 for the participating hospitals.
Study population
Consecutive adults admitted to one of the participating 
ICUs.
Eligibility criteria
Inclusion criteria for eligibility
1. Age≥18 years
2. Admitted to the ICU.
Exclusion criteria for eligibility
1. Admitted to the ICU with an acute neurological diag-
nosis (including acute stroke, traumatic brain injury, 
intracranial malignancy, anoxic coma). Prior non- acute 
stroke or another neurological condition without cog-
nitive deterioration is not an exclusion criterion.
2. Pregnancy or lactation.
3. History of ventricular arrhythmia including ‘torsade 
de pointes’ (TdP).
4. Known allergy to haloperidol.
5. History of dementia or an Informant Questionnaire on 
Cognitive Decline in the Elderly (IQCODE) score ≥412
6. History of malignant neuroleptic syndrome or parkin-
sonism (either Parkinson’s disease or another hypoki-
netic rigid syndrome).
7. Schizophrenia or other psychotic disorder.
8. Inability to conduct valid delirium screening assess-
ment (eg, coma, deaf, blind) or inability to speak the 
Dutch language.
9. Expected to die within 24 hours or leave the ICU with-
in 24 hours.
Inclusion criteria for randomisation
1. Delirium, as assessed with the Intensive Care Delirium 
Screening Checklist (ICDSC ≥4) or the Confusion 
Assessment Method for the ICU (positive CAM- ICU 
assessment), at the time of ICU admission or any ICU 
day after ICU admission.
2. Written informed consent obtained from the patient 
or their legal representative.
3. All eligibility inclusion criteria (from above) are still 
met.
Exclusion criteria for randomisation
1. Prolonged QT- interval (QTc >500 ms).
2. (recent) TdP.
3. (recent) Neuroleptic malignant syndrome or parkin-
sonism.
4. Evidence of acute alcohol (or substance) withdrawal 
requiring pharmacological intervention (eg, benzodi-
azepines or alpha-2 agonist) to treat.
5. The patient is expected to die within 24 hours or ex-
pected to leave the ICU within 24 hours.
6. No (previously) signed informed consent by patient or 
representative.
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7. Current participation in another intervention trial 
that is evaluating a medication, device or behavioural 
intervention.
Study outcomes
Main study outcome
ICU delirium and coma- free days (DCFDs) (up to 14 days 
after randomisation).
Secondary study outcomes
During ICU stay
 ► Richmond Agitation Sedation Scale (RASS).
 ► Maximum ICU Mobility Scale (IMS13) and day of 
maximum IMS.
 ► Quality of sleep (Richards- Campbell Sleep Ques-
tionnaire (RCSQ)14 and with a visual analogue scale 
between 1 and 7 assessing the sleep quality according 
to the nurse).
 ► Use of ‘escape medication’ for hallucinations and/or 
agitation (including atypical antipsychotics, alpha-2 
agonists, GABA agonists, opiates and ‘open- label’ 
haloperidol).
 ► Daily study drug dose corrected for body weight (mg/
kg).
 ► Self- extubation rate, removal of invasive devices 
(intravenous/intra- arterial catheters, drains and 
tubes).
 ► Adverse drug- associated events (prolonged QTc by 
EKG, muscle rigidity and other associated movement 
disorders (Simpson Angus Scale15) and ventricular 
arrhythmias including TdP).
 ► Blood pressure will be recorded previous to and 
1 hour after the first study drug dose (2.5 mg equiva-
lent) and 1 hour after the first 5 mg equivalent.
 ► Daily respiratory status (regarding endotracheal intu-
bation and mechanical ventilation).
 ► Time from randomisation to first resolution of 
delirium.
 ► Time to ‘readiness for discharge from the ICU’.
Hospital discharge
 ► Patient and family member well- being and experi-
ences associated with delirium during and after ICU 
stay with the ICU Memory Tool (ICU- MT16) and 
Delirium Experience Questionnaire (DEQ17).
28 days after randomisation
 ► Mortality rate.
3 months after randomisation
 ► Cognitive outcomes with a detailed cognitive assess-
ment battery of validated and repeatable measures 
of general cognition, memory, language, processing 
speed, attention and executive functioning, and mood 
(Montreal Cognitive Assessment (MOCA),18 Rey 
Auditory Verbal Learning Test,19 Semantic fluency,20 
Digit Span (WAIS- IV),21 Trail making tests A and 
B,22 Boston naming Test (short version),23 Hospital 
Anxiety and Depression Scale (HADS)24).
 ► Functional outcomes and quality of life (Short 
Form-36 (SF-36)25).
 ► Patient and family member well- being and experi-
ences associated with delirium during and after ICU 
stay with the ICU- MT,16 DEQ17 and Caregiver Strain 
Index (CSI26).
 ► Post- traumatic stress syndrome in participants 
and family members with the Impact of Event 
Scale–Revised.27
12 months after randomisation
 ► Cognitive outcomes with a detailed cognitive assess-
ment battery of validated and repeatable measures 
of general cognition, memory, language, processing 
speed, attention and executive functioning, and 
mood (MOCA,18 Rey Auditory Verbal Learning Test,19 
Semantic fluency,20 Digit Span (WAIS- IV),21 Trail 
making tests A and B,22 Boston naming Test (short 
version),23 HADS24).
 ► Functional outcomes and quality of life (SF-3625).
 ► Mortality rate.
A cost- effectiveness analysis will be performed in 
collaboration with the Department of Health Policy and 
Management of Erasmus University Rotterdam (see online 
supplemental appendix 2 for more detailed explanation). 
The tools for the secondary outcomes are mentioned in 
table 1 with overview of timing of assessments.
Treatment of subjects
Investigational product
Name: Haldol (haloperidol)
Mechanism: butyrophenone- derived anti- psychotic 
with mainly dopamine-2 receptor antagonistic properties
Placebo consists of sodium chloride for injection. 
Medical staff, patients and family will be blinded to the 
product containing haloperidol/placebo.
Summary of findings from clinical studies and of known and 
potential risks and benefits
See: Summary of Product Characteristics in online 
supplemental appendix 3 and Systematic Review (online 
supplemental appendix 4).
Dosages, dosage modifications and method of administration
The following dosing scheme will be used: start with halo-
peridol/placebo (further called: ‘study drug’) 2.5 mg 
intravenously q8h (because of delirium screening once 
every 8- hour shift) and increase to a maximum dose of 
5 mg intravenously q8h when delirium persists during the 
next 8- hour shift. Doses will be reduced (50% of dose) in 
the very old elderly (age ≥80 years). The study drug dose 
will be decreased (when dosage is 5 mg intravenously 
q8h) or stopped (when dose is 2.5 mg intravenously q8h) 
when delirium has resolved (or is un- assessable due to 
coma) for the next 24 hours (implying: three consecutive 
delirium assessments during three shifts). Dosages can be 
lowered also at the discretion of the treating physician 
in case of evident rigidity, which is in line with current 
routine practice. Standard clinical practice for the admin-
istration of haloperidol will be followed.
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Description and justification of route of administration and dosage
Administration of the study intervention via the intrave-
nous (vs the oral or enteral) route is the most feasible 
in critically ill patients—a population where gastrointes-
tinal dysfunction is prevalent and haloperidol absorption 
(ie, bioavailability) could be compromised. The dose of 
haloperidol or placebo equivalent to be used in the study 
is based on the following consideration: (1) Pharmaco-
kinetics/pharmacodynamics; (2) efficacy; (3) safety. A 
(pilot) study in Erasmus Medical Centre (n=14 critically 
ill patients, abstract presented at European Society of 
Intensive Care Medicine 2016) showed no adverse events 
(eg, no QTc >500 ms), low serum levels (1.5–2.2 µg/L) 
and no clear relation between serum level and delirium 
resolution with haloperidol dosages up to 2 mg intrave-
nously q8h (or: 3×2 mg intravenously). A feasibility trial 
of haloperidol for ICU delirium (MIND trial8) that used 
an average total daily dosage of 15 mg orally found higher 
serum levels (IQR 2.85–5.8 µg/L). No differences were 
found in QTc prolongation between treatment groups 
and placebo in this trial. None of these trials demon-
strated clinically important safety concerns associated with 
haloperidol administration. Finally, a recently published 
trial of haloperidol for ICU delirium using haloperidol/
placebo 10 mg intravenously q12h did not report any 
safety issues, using a QTc cut- off for safety of 550 ms, which 
may be regarded an indirect signal that such dosages are 
feasible and safe.28 The maximum dose of haloperidol of 
up to 5 mg intravenously q8h was further chosen because 
a previous Dutch guideline advocating the use of haloper-
idol recommended an intravenous haloperidol treatment 
dose of up to 20 mg/24- hour period.29 In our protocol, 
we chose q8h dosing (titrated up to 15 mg daily) given the 
greater potential susceptibility of critically ill adults to the 
side effects of haloperidol and the fact that this dosage 
is in line with existing haloperidol delirium protocols in 
several of the participating ICUs.
Table 1 Overview of timing of assessments, including required time investment per visit/questionnaire
Moment (months)
Neurocognitive 
tests
Patient and family 
experiences (time in 
min)
Functional 
outcomes
(SF-36)
Cost- effectivity 
questionnaires (EQ- 
5D- 5L, iMTA MCQ, 
iMTA PCQ) Other
Enrolment         Informed consent, 
IQCODE- N, 
pregnancy test (if 
applicable), EKG
ICU study period 
(3×/day)
        CAM- ICU/ICDSC, 
RASS
ICU study period 
(once daily)
        IMS, RCSQ. Only 
when on study 
medication: EKG, 
Simpson Angus 
Scale
0 (discharge from 
hospital)
  Patient: ICU- 
MT15+DEQ15
Family: DEQ2
      
1       30 min   
3 45–60 min Patient: IES- 
R5+ICU MT15+DEQ15
Family: IES- 
R5+CSI5+DEQ2
10 min 30 min   
6       30 min   
12 45–60 min   10 min 30 min   
Neurocognitive tests: Montreal Cognitive Assessment (MOCA), Rey Auditory Verbal Learning Test, Semantic fluency, Digit Span (WAIS- IV), 
Trailmaking tests A and B, Boston naming Test (short version), Hospital Anxiety and Depression Scale (HADS).
Simpson Angus Scale=measures muscle rigidity and other associated movement disorders.
With the exception of the neurocognitive tests, all aforementioned tools are questionnaires that can be administered at home. Real- life visits 
only need to be paid in order to perform the neurocognitive tests.
CSI, Caregiver Strain Index, assesses the strain experienced by the caregiver; DEQ, Delirium Experience Questionnaire, measures 
experiences linked to delirium; EKG, Electrocardiography; EQ- 5D- 5L, assesses the general health status; ICU- MT, ICU- Memory Tool, 
assesses the experience and memories of ICU admission; IES- R, Impact of Event Scale Revised, assesses distress linked to a traumatic 
experience (i.e. experiencing delirium); IMS, ICU Mobility Scale, measures mobility during ICU admission; iMTA MCQ, instituut Beleid & 
Management Gezondheidszorg Medical Consumption Questionnaire (healthcare use); IQCODE- N, Informant Questionnaire on Cognitive 
Decline in the Elderly – Dutch version; RCSQ, Richards- Campbell Sleep Questionnaire, measures quality of sleep; SF-36, Short Form-36, 
measures the health- related quality of life.
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Patient assessments
Rigidity will be monitored with the Simpson- Angus scale15 
and the Barnes Akathisia Rating Scale30 (see ‘Secondary 
study endpoints’ section) for study purposes only. The 
QTc interval will be measured daily before the administra-
tion of the second daily (afternoon) dose using a 12- lead 
EKG. When the QTc interval is found to be prolonged 
(>500 ms or an increase from baseline (=at randomis-
ation) of ≥60 ms31 32), all non- study medications having 
the potential to prolong the QTc will be held if clinically 
feasible. A Standard Operating Procedure (SOP) lists the 
drugs known to prolong the QTc. Eight hours later, if 
QTc prolongation persists, study medication will be held 
or tapered according to the SOP and only resumed when 
the EKGs (evaluation frequency increased to q8h in this 
situation) reveal QTc prolongation to have dissipated.
General medical management at participating ICUs
In the six original participating ICUs, institutional 
delirium guidelines, based on the 2013 PAD guidelines 
and a Dutch ICU delirium guideline, were rigorously 
implemented over a 3- year period (2012 to 2015).6 33 34 
During the inclusion period of the current trial, spot- 
checks will be performed by members of the investigative 
team at each centre to confirm delirium screening accu-
racy as a quality- of- assessments measure, and these will be 
documented in a qualitative manner.
Preparation and labelling of investigational medicinal product
Preparation and labelling will be done by the trial phar-
macist (‘Apotheek A15’) according to Good Manufac-
turing Practices guidelines. Apotheek A15 is certified for 
these procedures. Trial medication will be dispensed to 
the pharmacies of the trial sites by the Hospital Pharmacy 
of Erasmus MC. See online supplemental appendix 5 for 
a description of the drug accountability.
Escape medication
Knowing that half the subjects will be administered 
placebo, we anticipate two issues may affect the clinical 
management of enrolled patients: (1) agitation and (2) 
hallucinations.
Agitation management will be based on the following 
principles: (1) treat pain first with opioids; (2) use 
alpha-2 agonist for agitation that either persists or is not 
caused by pain; (3) GABA agonists (eg, benzodiazepines 
or propofol) are discouraged, but can be used on a short- 
term basis for the treatment of severe agitation (RASS ≥2) 
that cannot be effectively managed by other means.
Hallucination management will be based on the 
following principles: (1) pharmacological treatment may 
be withheld if the patient indicates they are not in distress; 
(2) for a patient in distress, a low- dose atypical antipsy-
chotic (eg, quetiapine 12.5 mg q8h) may be administered 
on a short- term basis until the distress resolves.
Because of the pragmatic design of this trial, within 
these boundaries, the treatment and dose of escape 
medication is left to the treating physician since these are 
part of routine practice. However, before start of rando-
misation, these management principles for agitation 
and hallucination will be thoroughly implemented first 
with the help of detailed SOP’s to enhance uniformity in 
participating centres. Adherence to escape medication 
regimens will be closely monitored. Open- label haloper-
idol administration is strongly discouraged during the 
trial but can be used if the ICU team considers it necessary 
for acute breakthrough delirium symptoms that cannot 
be managed within the management boundaries outlined 
previously. Open- label haloperidol will be documented.
Randomisation, blinding and treatment allocation
Legal representatives of eligible patients (when the 
patient is sedated or otherwise temporarily unable to 
consent) or the patient himself/herself will be asked 
for informed consent shortly after admission when the 
patient has no delirium or as soon as possible after admis-
sion when the patient already has delirium. Online supple-
mental appendix 6 contains an example of the patient 
consent form. In this study, the presence of delirium will 
be considered to be confirmed when the bedside nurse 
deemed the patient to have delirium based on assessment 
with the ICDSC or CAM- ICU, given the previous large- 
scale implementation project.33
Delirious patients who fulfil all inclusion but no exclu-
sion criteria, and for whom written informed consent 
has been obtained (as recorded in medical file), will be 
randomised. Randomisation coordination and start of a 
new case record form (CRF) will be guided by the elec-
tronic data capture (EDC) system of ALEA, constructed 
by the Clinical Trial Centre of the Erasmus Medical 
Centre and calibrated with the coordinating (Erasmus 
MC) and local pharmacies. We will randomise the 
recruited patients using a block design of eight patients 
in one block, and one block is assigned to a centre. We 
will have eight batches (numbered 1 through 8) of treat-
ment and placebo, with four batches of placebo and four 
treatment (haloperidol). Each block will have a random 
assignment of eight batch numbers, having four placebo 
and four haloperidol patients included (a combination of 
1 to 4 and 5 to 8 in random order). After eight patients 
are included in the study (ie, a block is full), a new block 
will be assigned to a centre.
On randomisation, the study drug with the corre-
sponding randomisation kit numbers 1–8 (based on 
eight medication batches consisting of either haloper-
idol or placebo) will be obtained from the hospital phar-
macy of each participating ICU. Each box from a batch/
kit contains 10 ampules (5 mg/1 mL) of haloperidol or 
placebo. If all ampules are used, a new box from the same 
medication kit number with 10 ampules will be used. 
Study drugs are administered on prescription in the elec-
tronic patient data management system (PDMS) and are 
double- checked by ICU nurses before administration, 
which is similar to regular practice. Furthermore, the kit 
number was noted on randomisation in the medical file 
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and the kit number could be retrieved at any time from 
the PDMS after first prescription on randomisation.
Blinding of the medication will be performed by the 
pharmacy, based on a randomisation list that will be gener-
ated electronically through a randomisation module in 
the EDC system of ALEA. Randomisation will be stratified 
per study centre (ie, equal number of patients in both 
study groups; see ‘Statistical analysis’ section). Only the 
involved pharmacists and the trial statistician are aware 
of the contents of each medication kit. Only the local 
(site) pharmacists are able to unblind study treatment of 
a patient in case of an emergency. Except for the hospi-
tal’s pharmacist responsible for the randomisation list, 
all other involved personnel with the study, caregivers, 
patients or their representatives will remain unaware of 
the treatment groups until the time of Database Lock. 
The unblinding procedure is specified in online supple-
mental appendix 7.
Follow- up procedures will be performed according 
to designated SOPs. When possible and preferred by 
patients or families, questionnaires will be sent or visits 
planned at home when possible, for example, for inca-
pacitated participants.
Withdrawal of individual subjects
Subjects can leave the study at any time for any reason if 
they wish to do so without any consequences. The investi-
gator can decide to withdraw a subject from the study for 
urgent medical reasons.
Follow-up of subjects withdrawn from treatment
Data of withdrawn patients will remain in the database 
for statistical analysis purposes but will not be subject 
to follow- up. When patients specifically withdraw their 
consent for usage of their data, these data will be removed 
from the database and excluded from all analyses.
Premature termination of the study
The sponsor may decide to terminate the study prema-
turely based on the following criteria:
 ► There is evidence of an unacceptable risk for study 
patients (ie, safety issue).
 ► There is reason to conclude that continuation of 
the study cannot serve a scientific purpose following 
confirmation of the Data Safety Monitoring Board 
(DSMB).
 ► The DSMB recommends to end the trial based on 
viable arguments other than described above.
The following stopping rules have been determined by 
the DSMB and have been laid down in a DSMB charter:
 ► Early stopping of one individual participant, for 
example, to clear benefit or harm of a treatment or 
the occurrence of serious adverse reactions or events 
in one patient. In this case, de- blinding of this single 
patient may be necessary.
 ► Stopping of the trial as a whole to clear benefit or 
harm of a treatment or the occurrence of serious 
adverse reactions or events. As a result, further patient 
enrolment will be stopped. De- blinding may be neces-
sary for all patients.
Reasons to stop the study include
 ► Advice to do so from DSMB.
 ► Interim analysis shows a significant benefit differ-
ence between the treatment groups which will not be 
expected to change after inclusion of all subject as per 
the power analysis.
Suspected unexpected serious adverse reactions 
(SUSARs) are not expected due to the vast experience in 
clinical practice with the study drug (haloperidol).
If the study is terminated, the Medical Ethics Commit-
tees of all participating hospitals and the Central 
Committee on Research Involving Human Subjects 
(CCMO) will be notified.
Safety reporting
Adverse events (AEs), serious adverse events (SAEs) and SUSARs
Adverse events
AEs are defined as any undesirable experience occurring 
to a subject during the study, whether or not considered 
related to the investigational product. Since patients 
admitted to an ICU are critically ill and present with many 
AEs, only possible adverse drug- related events (on days of 
study drug administration: prolonged QTc by EKG, muscle 
rigidity and associated movements disorders (Simpson 
Angus Scale)), as indicated by the subject or observed 
by the investigator or his staff occurring from the date 
of randomisation until 14 days later or discharge from 
ICU or death (whichever comes first), will be recorded 
in the CRF. In addition, the following AEs will be assessed 
daily during 14 days after randomisation: epilepsy, tachy-
cardia, hypotension (not explained otherwise), hepatic 
dysfunction (not explained otherwise), leucopenia (not 
explained otherwise) and bronchospasms (not explained 
otherwise).
Serious adverse events
An SAE is any untoward medical occurrence or effect, 
occurring during the 14- day study period at the ICU, that 
(the SAEs for the purpose of the study are shown in italics 
per item)
 ► Results in death;
 – Death will always be reported as an SAE
 ► Is life threatening (at the time of the event);
 – Ventricular arrhythmia or malignant neuroleptic 
syndrome
 ► Requires hospitalisation or prolongation of existing 
inpatients’ hospitalisation;
 – Not to be expected; only applicable when the site investiga-
tor is able to explicitly show a relationship
 ► Results in persistent or significant disability or 
incapacity;
 – Not to be expected; only applicable when the site investiga-
tor is able to explicitly show a relationship
 ► Is a congenital anomaly or birth defect; (Not appli-
cable) or
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 ► Any other important medical event that did not result 
in any of the outcomes listed above due to medical or 
surgical intervention but could have been based on 
appropriate judgement by the investigator.
Statistical analysis
Primary and secondary study parameter(s)
Statistical analysis will be done according to intention- 
to- treat principle. All randomised participants will be 
included. The primary outcome is DCFDs, defined as the 
number of days in the first 14 days after randomisation 
during which the patient is alive without delirium and 
not in coma from any cause.7 Patients who are discharged 
before the 14- day study period has ended will be recorded 
as delirium and coma free after discharge.8 35 In addition, 
we will assume all patients who died within 14 days after 
randomisation to have 0 DCFDs.7 Differences between 
DCFDs between the haloperidol group and placebo 
group will be analysed using Poisson regression analysis, 
with adjustment for differences in baseline characteris-
tics between treatment groups (when present) and for 
the different centres. We will collect data with regards 
to baseline demographics: age, sex, admission diagnosis 
category, APACHE II and APACHE IV, Sequential Organ 
Failure Assessment (SOFA) score, ICU days before study 
entry and pre- admission delirium duration in participants 
with delirium on admission. Pre- defined sub- analyses will 
include efficacy stratified by (1) agitated, mixed- type or 
hypoactive delirium; (2) the presence of hallucinations 
or delusions; (3) delirium severity (based on ICDSC 
score: low delirium severity=mean ICDSC score of 4 to 5; 
medium delirium severity=mean ICDSC score 5 to 7; high 
delirium severity=ICDSC score 7 to 8); and (4) sedation- 
related, hypoxic, metabolic or septic delirium. For cogni-
tive and functional outcomes assessed with designated test 
batteries, non- parametric or parametric tests will be used 
depending on normality of scaled test results. Mortality 
risk will be assessed as a binary endpoint. A more detailed 
statistical analysis plan, to be drawn up before Data Base 
Lock, will be drafted for publication separately.
INTERIM ANALYSIS
Pre- planned interim analyses will be performed at one- 
third and two- thirds of the trial’s course (first analysis 
ideally estimated at 6 months after start of trial), as deter-
mined by the DSMB charter or otherwise when the DSMB 
requests it.
Sample size calculation
To achieve statistically significant results (p<0.05) with a 
power of 90% and a true treatment difference of 1 day 
for the primary outcome (from 3.2 DCFDs in the placebo 
group to 4.2 in the haloperidol group, SD in both groups 
is equal to 4.2), 371 patients are needed in each group 
(n=742). These estimates are derived from the previous 
implementation study, which included 4727 patients in 
three 4- month periods in the same six participating ICUs 
and found delirium incidence of 27% (and increase of 
DCFDs from 60% to 70%).33 Consequently, presuming 
an informed consent rate of 40%, we need 18 months to 
encounter 1900 patients with a newly diagnosed delirium 
to include the required 742 patients. Because of estimated 
workload due to follow- up visits, including, for example, 
neurocognitive testing, we propose to select a conve-
nience sample of two- thirds of ICU survivors (estimated 
around 400 of 575 survivors) as a random sample for the 
cognitive, functional and secondary outcome variables.
Patient and public involvement
During the design and conduct of the study, we involved 
two ex- ICU patients as patient- perspective representatives. 
The primary research question, its outcome measures 
and the burden of the intervention have been assessed 
and found relevant by these patient- representatives. 
The role and tasks of the patient- representatives for the 
study have been detailed as (1) to help select meaningful 
assessment tools of patient and family experiences during 
and after ICU stay; (2) act as liaison between the study 
management team and the Dutch foundation ‘Family 
and patient Centred Intensive Care’ (FCIC; one repre-
sentative is a formal representative for FCIC); (3) act as 
members of the Stakeholders group to provide advice on 
the study contents, execution and course on a regular 
basis to ensure the patient and family perspective; (4) 
advise on the contents of the patient information form 
and the informed consent procedure; (5) advise on ways 
to minimise loss to follow- up for the functional and cogni-
tive outcome assessments; (6) advise on contents and 
organisation of symposia during the study on delirium 
and its consequences with the aim to better inform partic-
ipants of the study and their family members and maxi-
mise their involvement; and (7) advise on the contents of 
the supporting website of the trial. Study participants will 
be informed about the most important results of the trial, 
either by post or symposium, when they indicate this on 
the informed consent letter.
ETHICS AND DISSEMINATION
The study has been approved by the Medical Ethics 
Committee of the Erasmus University Medical Centre 
Rotterdam (MEC2017-511) and the Institutional Review 
Boards of participating sites. The study will be conducted 
according to the principles of the Declaration of Helsinki 
(version, date, see for the most recent version: www. 
wma. net) and in accordance with the Medical Research 
Involving Human Subjects Act (WMO) and other guide-
lines, regulations and Acts.
Recruitment and consent
Recruitment of eligible patients will be done at admis-
sion. Informed consent for possible participation (ie, only 
when participants develop delirium at the ICU) will be 
obtained from subjects who are not expected to leave the 
4300.7802.430. P
rotected by copyright.
 on N
ovem
ber 18, 2020 at E
rasm
us M
edical / X
51
http://bm
jopen.bm
j.com
/
B
M
J O
pen: first published as 10.1136/bm
jopen-2019-036735 on 23 S
eptem
ber 2020. D
ow
nloaded from
 
8 Smit L, et al. BMJ Open 2020;10:e036735. doi:10.1136/bmjopen-2019-036735
Open access 
ICU within the first 24 hours after admission and are not 
yet delirious. Informed consent will be obtained from the 
patient or (if the patient is unable to consent) from the 
patient’s representative. This procedure of prior request 
for informed consent will facilitate randomisation when 
the patient indeed develops delirium because rando-
misation can then be performed 24/7 since informed 
consent is already obtained and delirium often surfaces 
during the evening and night when obtaining informed 
consent is difficult. The informed consent procedure 
will be clearly delineated from the randomisation proce-
dure. Importantly, when a patient with prior informed 
consent develops delirium and can thus be randomised, 
still a pre- randomisation check with regard to inclusion 
and exclusion criteria will be performed to confirm that 
the patient fulfils the inclusion, and not the exclusion 
criteria (because this may change over time). A team of 
dedicated research and ICU nurses and physicians (local 
principal investigator (PI), PhD student, PI, post- doc) will 
be trained to perform the informed consent procedures 
and help with the randomisations. Moreover, a 24/7 
study consultation telephone number will be opened 
to help with problems or question during the study. A 
second type of randomisation concerns patients who are 
delirious at admission to ICU. These patients’ next- of- kin 
will be asked to grant permission to participate by means 
of informed consent when they are legally representative 
for the patients and the patient has no contraindications. 
After informed consent is obtained, the patient can be 
randomised.
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